Related Experiment Video

Updated: Jul 17, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

FOXR2-Mediated CNS Neuroblastoma in a Pediatric Patient Treated With Multimodal Therapy Including Proton Craniospinal

Waseem Syed1, Chetan Shah2, Leticia Schaefer3

  • 1College of Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, USA.

Cureus
|July 16, 2026
PubMed

Insights

This case study details the successful treatment of a rare FOXR2-activated central nervous system (CNS) neuroblastoma in a young child. Modern therapies, including proton craniospinal irradiation (CSI), improved outcomes while minimizing toxicity.

Area of Science:

  • Pediatric Oncology
  • Neuro-oncology
  • Radiation Oncology

Background:

  • FOXR2-activated central nervous system (CNS) neuroblastoma is a rare, aggressive embryonal tumor.
  • These tumors often present with leptomeningeal dissemination and have a poor prognosis without intensive treatment.
Keywords:
foxr2mrineuroblastomaproton therapyradiology

More Related Videos

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model09:57

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

Published on: June 4, 2017

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...